Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jan 12, 2021 2:32pm
151 Views
Post# 32277643

RE:RE:RE:RE:Anyone want to guess at RBC's new target price?

RE:RE:RE:RE:Anyone want to guess at RBC's new target price?There may be some truth to that line of thinking and it is what the company is selling but count me  skeptical based on 40+ years of experience. Obviously, I hope you and the company are right about that. If new institutional holders compel US analysts to pick up coverage fo the stock, that will be a nice benefit from the deal. But the cost is way too high and other lesser NASH firms have found much more attractive ways to do deals at better prices and resulting in better analysts covering them. There may be benefits in time but it will always be a deal that could have been done at a better time for a better price with better side benefits. 

ggg088 wrote: In my understanding, @2.75 is the cost for the institutional investor, they must have done a comprehensive research about the THTX mangement team, operation,finance and R&D, they will have further understanding than retailer investors, because they ave more resources and want to make profit . So why this deal is a negative news? From the long term trend, the sp would be going up because more institutional investor will be involved in this business.


<< Previous
Bullboard Posts
Next >>